- Zacks•3 days ago
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•6 days ago
AVEO Oncology today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology Annual Meeting, held June 2-6, 2017.
- Business Wire•13 days ago
AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues
AVEO Oncology today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency Day 180 List of Outstanding Issues related to the Marketing Authorization Application for tivozanib as a first-line treatment for renal cell carcinoma.
AVEO : Summary for AVEO Pharmaceuticals, Inc. - Yahoo Finance
AVEO Pharmaceuticals, Inc. (AVEO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.56 x 100|
|Ask||0.63 x 3000|
|Day's Range||0.58 - 0.60|
|52 Week Range||0.50 - 1.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|